Entera Bio prices USD 275 million private placement at USD 2.04 per share

Entera Bio priced an oversubscribed private placement expected to raise USD 275 million in gross proceeds.

The transaction is led by BVF Partners, with participation from several healthcare-focused investors; closing is expected around July 28, 2026.

The structure includes 122,961,215 ordinary shares at USD 2.04 each, with pre-funded warrants for up to 11,842,695 shares.

Proceeds are expected to extend cash runway into 2030, funding Phase 3 registrational studies for the EB613 oral osteoporosis tablet.

BVF will gain the right to designate two board directors upon closing, subject to standard eligibility requirements.